Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|May 15, 2020
ASCRS 2020: TearClear CEO shares company's vision, mission for future
Author(s)Alex Delaney-Gesing
Advertisement
Ophthalmology Times' Sheryl Stevenson speaks with Robert Dempsey, TearClear's new CEO, on his goals for the company, its mission and vision in the future of the coronavirus, as well as what to keep an eye out for at the 2020 ASCRS virtual meeting.
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP
3
OCT-980 receives FDA orphan drug designation for retinitis pigmentosa
4
Mediterranean diet linked to slower AMD progression across stages
5